nach oben

Acta Neuropathologica

Erschienen in:

01.09.2006 | Original Paper

Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?

verfasst von: Kurt A. Jellinger, Johannes Attems

Erschienen in: Acta Neuropathologica | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

The morphological differentiation of Parkinson disease with dementia (PDD) and dementia with Lewy bodies (DLB) is a matter of discussion. The objective of this study was to investigate the regional distribution of ß-amyloid (Aß) plaques, α-synuclein (AS), and pathology in both disorders. The basal ganglia from 17 age-matched patients of PDD and DLB each were immunohistochemically examined with variable degrees of associated Alzheimer pathology using antibodies to Aß, AS, and tau. DLB brains showed a significantly higher burden of (diffuse) amyloid plaques in the putamen and caudate nucleus and slightly more severe tau pathology than PDD brains despite similar neuritic Braak stages. Phases of Aß development in DLB brains often, but inconsistently, correlated with both neuritic Braak stages and severity of striatal Aß load, while these correlations were almost never seen in PDD cases with Alzheimer lesions. They also revealed a higher burden of AS-lesions (both Lewy neurites and Lewy bodies) than PDD cases that commonly had a paucity of all three types of lesion. The globus pallidus was virtually spared in both phenotypes. Differences in AS and Aß pathologies and much less of tau lesions in the striatum support a morphologic distinction between PDD and DLB, which may be of pathophysiologic importance, but the causes of these differences are unclear.

Aarsland D, Ballard CG, Halliday G (2004) Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 17:137–145PubMedCrossRef

Aarsland D, Perry R, Brown A, Larsen JP, Ballard C (2005) Neuropathology of dementia in Parkinson’s disease: a prospective, community-based study. Ann Neurol 58:773–776PubMedCrossRef

Allsop D, Haga SI, Haga C, Ikeda SI, Mann DM, Ishii T (1989) Early senile plaques in Down’s syndrome brains show a close relationship with cell bodies of neurons. Neuropathol Appl Neurobiol 15:531–542PubMedCrossRef

Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW (2002) Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 59:102–112PubMedCrossRef

Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Ruther E, Kornhuber J, Otto M, Wiltfang J (2006) CSF amyloid-beta-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 129:1177–1187PubMedCrossRef

Braak H, Braak E (1990) Alzheimer’s disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol 49:215–224PubMedCrossRef

Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol Berl 82:239–259PubMedCrossRef

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef

Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410PubMed

10.

Brilliant MJ, Elble RJ, Ghobrial M, Struble RG (1997) The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer’s disease. Neuropathol Appl Neurobiol 23:322–325PubMedCrossRef

11.

Brown DF, Dababo MA, Bigio EH, Risser RC, Eagan KP, Hladik CL, White CL 3rd (1998) Neuropathologic evidence that the Lewy body variant of Alzheimer disease represents coexistence of Alzheimer disease and idiopathic Parkinson disease. J Neuropathol Exp Neurol 57:39–46PubMedCrossRef

12.

Bugiani O, Giaccone G, Frangione B, Ghetti B, Tagliavini F (1989) Alzheimer patients: preamyloid deposits are more widely distributed than senile plaques throughout the central nervous system. Neurosci Lett 103:263–268PubMedCrossRef

13.

Cataldo AM, Barnett JL, Mann DM, Nixon RA (1996) Colocalization of lysosomal hydrolase and beta-amyloid in diffuse plaques of the cerebellum and striatum in Alzheimer’s disease and Down’s syndrome. J Neuropathol Exp Neurol 55:704–715PubMedCrossRef

14.

Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O’Brien JT (2005) Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson’s disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 32:1176–1185PubMedCrossRef

15.

Cousins DA, Burton EJ, Burn D, Gholkar A, McKeith IG, O’Brien JT (2003) Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer’s disease: an MRI study. Neurology 61:1191–1195PubMed

16.

Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ (2002) Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 52:205–210PubMedCrossRef

17.

Duyckaerts C (2002) Is Parkinson’s disease with dementia and dementia with Lewy body the same disease? Mov Disord 17(Suppl 5):S9

18.

Galpern WR, Lang AE (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 59:449–458PubMedCrossRef

19.

Gearing M, Wilson RW, Unger ER, Shelton ER, Chan HW, Masters CL, Beyreuther K, Mirra SS (1993) Amyloid precursor protein (APP) in the striatum in Alzheimer’s disease: an immunohistochemical study. J Neuropathol Exp Neurol 52:22–30PubMedCrossRef

20.

Gearing M, Levey AI, Mirra SS (1997) Diffuse plaques in the striatum in Alzheimer disease (AD): relationship to the striatal mosaic and selected neuropeptide markers. J Neuropathol Exp Neurol 56:1363–1370PubMedCrossRef

21.

Geser F, Wenning GK, Poewe W, McKeith I (2005) How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 20(Suppl 12):S11–S20PubMedCrossRef

22.

Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, Persad C, Heumann M, Wernette K (2004) Striatal monoamine terminals in Lewy body dementia and Alzheimer’s disease. Ann Neurol 55:774–780PubMedCrossRef

23.

Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M et al (1990) The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology 40:1–8PubMed

24.

Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54:1916–1921PubMed

25.

Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56:1095–1097PubMedCrossRef

26.

Iseki E, Togo T, Suzuki K, Katsuse O, Marui W, de Silva R, Lees A, Yamamoto T, Kosaka K (2003) Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol Berl 105:265–270PubMed

27.

Iseki E (2004) Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson’s disease or Alzheimer’s disease. Neuropathology 24:72–78PubMedCrossRef

28.

Ito H, Kusaka H, Matsumoto S, Imai T (1996) Striatal efferent involvement and its correlation to levodopa efficacy in patients with multiple system atrophy. Neurology 47:1291–1299PubMed

29.

Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13:45–53PubMedCrossRef

30.

Jellinger KA, Seppi K, Wenning GK (2003) Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol Berl 106:188–189PubMedCrossRef

31.

Jellinger KA (2004) Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 111:219–235CrossRef

32.

Jellinger KA (2006) Neuropathology of dementia in Parkinson’s disease. Ann Neurol 59:727PubMedCrossRef

33.

Joachim CL, Morris JH, Selkoe DJ (1989) Diffuse senile plaques occur commonly in the cerebellum in Alzheimer’s disease. Am J Pathol 135:309–319PubMed

34.

Kovari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, Giannakopoulos P (2003) Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol Berl 106:83–88PubMed

35.

Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD, Kukull WA, Leverenz JB, Cherrier MM (2005) Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 64:2069–2073PubMedCrossRef

36.

Lach B, Grimes D, Benoit B, Minkiewicz-Janda A (1992) Caudate nucleus pathology in Parkinson’s disease: ultrastructural and biochemical findings in biopsy material. Acta Neuropathol Berl 83:352–360PubMedCrossRef

37.

Lees AJ (2002) Parkinson’s disease with dementia (PDD) is the same clinicopathological entity as dementia with Lewy bodies (DLB) (abstr). Mov Disord 17(Suppl 5):S9

38.

Liang T, Noorigian JV, Duda JE (2006) Does striatal pathology distinguish DLB from PDD? Mov Disord 21(Suppl 13):S69–S70

39.

Marui W, Iseki E, Kato M, Akatsu H, Kosaka K (2004) Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer’s disease. Acta Neuropathol 108:121–128PubMedCrossRef

40.

McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMed

41.

McKeith IG, Perry EK, Perry RH (1999) Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on dementia with Lewy bodies. Neurology 53:902–905PubMed

42.

McKeith IG, Mosimann UP (2004) Dementia with Lewy bodies and Parkinson’s disease. Parkinsonism Relat Disord 10(Suppl 1):S15–18PubMedCrossRef

43.

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRef

44.

Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486PubMed

45.

Nakabayashi J, Yoshimura M, Morishima-Kawashima M, Funato H, Miyakawa T, Yamazaki T, Ihara Y (1998) Amyloid beta-protein (A beta) accumulation in the putamen and mammillary body during aging and in Alzheimer disease. J Neuropathol Exp Neurol 57:343–352PubMedCrossRef

46.

Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y (2004) Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov Disord 19:60–67PubMedCrossRef

47.

O’Brien J, Ames D, McKeith I, Chiu E (eds) (2006) Dementia with Lewy bodies and Parkinson’s disease dementia. Taylor & Francis, London

48.

Pappolla MA, Omar RA, Vinters HV (1991) Image analysis microspectroscopy shows that neurons participate in the genesis of a subset of early primitive (diffuse) senile plaques. Am J Pathol 139:599–607PubMed

49.

Parkkinen L, Pirttila T, Tervahauta M, Alafuzoff I (2005) Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. Neuropathology 25:304–314PubMedCrossRef

50.

Perneczky R, Mosch D, Neumann M, Kretzschmar H, Muller U, Busch R, Forstl H, Kurz A (2005) The Alzheimer variant of Lewy body disease: a pathologically confirmed case-control study. Dement Geriatr Cogn Disord 20:89–94PubMedCrossRef

51.

Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC (2005) A beta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 26:1183–1192PubMedCrossRef

52.

Porritt MJ, Kingsbury AE, Hughes AJ, Howells DW (2006) Striatal dopaminergic neurons are lost with Parkinson’s disease progression. Mov Disord (submitted)

53.

Probst A, Langui D, Ipsen S, Robakis N, Ulrich J (1991) Deposition of beta/A4 protein along neuronal plasma membranes in diffuse senile plaques. Acta Neuropathol Berl 83:21–29PubMedCrossRef

54.

Richard IH, Papka M, Rubio A, Kurlan R (2002) Parkinson’s disease and dementia with Lewy bodies: one disease or two? Mov Disord 17:1161–1165PubMedCrossRef

55.

Rudelli RD, Ambler MW, Wisniewski HM (1984) Morphology and distribution of Alzheimer neuritic (senile) and amyloid plaques in striatum and diencephalon. Acta Neuropathol Berl 64:273–281PubMedCrossRef

56.

Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S (2003) Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 62:644–654PubMed

57.

Suzuki M, Desmond TJ, Albin RL, Frey KA (2002) Striatal monoaminergic terminals in Lewy body and Alzheimer’s dementias. Ann Neurol 51:767–771PubMedCrossRef

58.

Thal DR, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H (2000) Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 59:733–748PubMed

59.

Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J (2006) What best differentiates Lewy body from Alzheimer’s disease in early-stage dementia? Brain 129:729–735PubMedCrossRef

60.

Tsuboi Y, Dickson DW (2005) Dementia with Lewy bodies and Parkinson’s disease with dementia: are they different? Parkinsonism Relat Disord 11(Suppl 1):S47–S51PubMedCrossRef

61.

Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, Perry R, McKeith I, Katona CL (2004) Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 62:1568–1572PubMed

62.

Wenning GK, Jellinger KA (2005) The role of alpha-synuclein and tau in neurodegenerative movement disorders. Curr Opin Neurol 18:357–362PubMedCrossRef

63.

Wolf DS, Gearing M, Snowdon DA, Mori H, Markesbery WR, Mirra SS (1999) Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. Alzheimer Dis Assoc Disord 13:226–231PubMedCrossRef

64.

Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, Samii A, Deutch AY, Montine TJ (2005) Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64:545–547PubMed

Titel: Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?
verfasst von: Kurt A. Jellinger
Johannes Attems
Publikationsdatum: 01.09.2006
Verlag: Springer-Verlag
Erschienen in: Acta Neuropathologica / Ausgabe 3/2006
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-006-0088-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2006

Fragmentation of Golgi apparatus of nigral neurons with α-synuclein-positive inclusions in patients with Parkinson’s disease

Kurt Jellinger Prize 2007 for Outstanding Scientific Writing in Neuropathology

Monocyclic and dicyclic hydrocarbons: structural requirements for proximal giant axonopathy

A missense mutation in the WD40 domain of murine Lyst is linked to severe progressive Purkinje cell degeneration

The inflammatory reaction pattern distinguishes primary dysferlinopathies from idiopathic inflammatory myopathies: an important role for the membrane attack complex

51st Annual Meeting of the German Society of Neuropathology and Neuroanatomy

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Update Neurologie